转移性神经内分泌肿瘤患者接受肽受体放射性药物治疗的全身肿瘤反应异质性
本研究回顾性纳入18例接受[177Lu]Lu-DOTATATE肽受体放射性药物治疗的转移性神经内分泌肿瘤患者,利用深度学习模型在系列[68Ga]Ga-DOTATATE PET/CT上勾画并追踪病灶感兴趣区。结果显示全部患者(100%)在首次随访即出现反应异质性,提示全面的病灶层面评估对准确理解神经内分泌肿瘤对肽受体放射性药物治疗的反应至关重要。
要点
- 18例患者共67次扫描勾画出3289个病灶感兴趣区,确定1459条病灶追踪轨迹。
- 全部患者(100%)在首次随访扫描即表现为疾病反应异质性。
- 10例有超过1次随访扫描的患者均显示病灶摄取呈非单调变化。
核心结论
- 据作者所知,这是首项按单个病灶感兴趣区全面定量评估反应的研究。
- 全部患者(100%)观察到反应异质性,提示全面的病灶层面反应评估对准确理解神经内分泌肿瘤对肽受体放射性药物治疗的反应至关重要。
研究设计与样本
- 回顾性单机构研究,纳入接受[177Lu]Lu-DOTATATE肽受体放射性药物治疗并在基线、治疗期间及治疗后行[68Ga]Ga-DOTATATE PET/CT的转移性神经内分泌肿瘤患者。
- 采用深度学习模型识别并勾画非生理性示踪剂摄取增高区域(病灶感兴趣区),自动分析各病灶感兴趣区摄取、跨时间点匹配并分类。
- 共纳入18例患者,接受2至7次[68Ga]Ga-DOTATATE PET/CT扫描。
主要发现
- 67次扫描共勾画3289个病灶感兴趣区(每幅图像中位24个),确定1459条病灶感兴趣区追踪轨迹(每例患者中位49条)。
- 所有患者在首次随访扫描时均出现疾病反应异质性。
- 10例有超过1次随访扫描的患者均显示病灶感兴趣区摄取呈非单调变化。
- 首次随访含新发病灶感兴趣区的129条轨迹中,80条(62%)在最终随访时消退;而首次随访病灶感兴趣区消失的60条轨迹中,仅12%(7/60)在最终随访时重新出现。
关键数值与推荐
- 病灶感兴趣区按ΔSUVtotal分类:消失、降低(ΔSUVtotal < -30%)、稳定(-30% ≤ ΔSUVtotal ≤ 30%)、升高(ΔSUVtotal > 30%)或新发。
- 患者治疗后同时存在新发或升高病灶感兴趣区及降低或消失病灶感兴趣区时,判定为反应异质性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with metastatic neuroendocrine tumors (NETs) can present with hundreds of lesions, and each lesion might have a unique response pattern to peptide receptor radiopharmaceutical therapy (PRRT). This response heterogeneity has been observed but is poorly understood. In this work, we perform a quantitative analysis of longitudinal PET/CT scans to comprehensively characterize the NET response to PRRT. Methods: NET patients treated with [177Lu]Lu-DOTATATE PRRT imaged at baseline, during, and after PRRT with [68Ga]Ga-DOTATATE PET/CT were enrolled in this retrospective single-institutional study. A deep-learning model was used to identify and contour regions of nonphysiological elevated tracer uptake (lesion-regions of interest [ROIs]). An automated analysis was performed to identify, contour, and quantify the individual lesion-ROI uptake, match ROI between time points, and categorize each lesion-ROI as disappearing, decreasing (ΔSUVtotal < -30%), stable (-30% ≤ ΔSUVtotal ≤ 30%), increasing (ΔSUVtotal > 30%), or new. A patient was considered to have response heterogeneity if both new or increasing lesion-ROIs and decreasing or disappearing lesion-ROIs were present after therapy. Results: Eighteen patients who received between 2 and 7 [68Ga]Ga-DOTATATE PET/CT scans were enrolled. In total, 3,289 lesion-ROIs were contoured in the 67 scans acquired (median of 24 lesion-ROIs per image), and 1,459 lesion-ROI tracks, defined as the path that each unique lesion-ROI follows across all time points, were determined by the ROI tracking method (median of 49 tracks per patient). All patients presented with disease response heterogeneity at the first follow-up scan. All 10 patients with more than 1 follow-up scan showed nonmonotonic change in lesion-ROI uptake. Of 129 tracks containing new lesion-ROIs at the first follow-up, 80 (62%) eventually resolved on final follow-up, whereas only 12% (7/60) of the tracks with lesion-ROIs disappearing at the first follow-up scan returned on final follow-up. Conclusion: To the best of our knowledge, this is the first study to evaluate response comprehensively and quantitatively in terms of individual lesion-ROIs. Response heterogeneity was observed in 100% of the patients, which suggests that comprehensive, lesion-level, response assessment is vital for the accurate understanding of the NET response to PRRT.
引用
- Santoro-Fernandes V, Schott B, Weisman AJ, et al. Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy. J Nucl Med. 2025. PMID: 39947917. doi:10.2967/jnumed.124.267809
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。